 | Up a level |
Hitz, F; Fischer, N; Pabst, Th; Caspar, C; Berthod, G; Eckhardt, K; Berardi Vilei, S; Zucca, E; Mey, U; On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (2013). Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of hematology, 92(8), pp. 1033-1040. Berlin: Springer 10.1007/s00277-013-1751-z
